The management of cancer in the elderly: Targeted therapies in oncology

Immunity and Ageing

Volumn 5, Issue , 2008, Pages

  Agostara, Biagio ^a   Carruba, Giuseppe ^a   Usset, Antonella ^a  

^a Ospedale Oncologico M Ascoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 2; IRINOTECAN; LAPATINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB;

ACNE; ADJUVANT THERAPY; AGING; ANAPHYLAXIS; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLEEDING; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ELDERLY CARE; FATIGUE; FEVER; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART DISEASE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG EDEMA; LUNG FIBROSIS; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPENIA; ONCOLOGY; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; THROMBOSIS;

EID: 60849103502     PISSN: 17424933     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4933-5-16     Document Type: Review

References (43)

1. Cobleigh MA Vogel CL Tripathy D Robert NJ Scholl S Fehrenbacher L Wolter JM Paton V Shak S Lieberman G Slamon DJ "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease" J Clin Oncol 1999, 17(9):2639-48. 10561337
2. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajamonde A Fleming T Eiermann W Wolter J Pegram M Baselga J Norton L "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2" N Engl J Med 2001, 344(11):783-92. 10.1056/NEJM200103153441101 11248153
3. Burstein HJ Kuter I Campos SM Gelman RS Tribou L Parker LM Manola J Younger J Matulonis U Bunnell CA Partridge AH Richardson PG Clarke K Shulman LN Winer EP "Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer" J Clin Oncol 2001, 19(10):2722-30. 11352965
4. Vogel CL Cobleigh MA Tripathy D Gutheil JC Harris LN Fehrenbacher L Slamon DJ Murphy M Novotny WF Burchmore M Shak S Stewart SJ Press M "Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer" J Clin Oncol 2002, 20(3):719-26. 10.1200/JCO.20.3.719 11821453
5. Burstein HJ Harris LN Marcom PK Lambert-Falls R Havlin K Overmoyer B Friedlander RJ Jr Gargiulo J Strenger R Vogel CL Ryan PD Ellis MJ Nunes RA Bunnell CA Campos SM Hallor M Gelman R Winer EP "Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm" J Clin Oncol 2003, 21(15):2889-95. 10.1200/ JCO.2003.02.018 12885806
6. O'Shaughnessy JA Vukelja S Marsland T Kimmel G Ratnam S Pippen JE "Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer" Clin Breast Cancer 2004, 5(2):142-7. 10.3816/CBC.2004.n.019 15245619
7. Marty M Cognetti F Maraninchi D Snyder R Mauriac L Tubiana-Hulin M Chan S Grimes D Antón A Lluch A Kennedy J O'Byrne K Conte P Green M Ward C Mayne K Extra JM "Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group" J Clin Oncol 2005, 23(19):4265-74. 10.1200/JCO.2005.04.173 15911866
8. Robert N Leyland-Jones B Asmar L Belt R Ilegbodu D Loesch D Raju R Valentine E Sayre R Cobleigh M Albain K McCullough C Fuchs L Slamon D "Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer" J Clin Oncol 2006, 24(18):2786-92. 10.1200/JCO.2005.04.1764 16782917
9. Schaller G Fuchs I Gonsch T Weber J Kleine-Tebbe A Klare P Hindenburg HJ Lakner V Hinke A Bangemann N "Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes" J Clin Oncol 2007, 25(22):3246-50. 10.1200/JCO.2006.09.6826 17577021
10. Bartsch R Wenzel C Altorjai G Pluschnig U Rudas M Mader RM Gnant M Zielinski CC Steger GG "Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer" J Clin Oncol 2007, 25(25):3853-8. 10.1200/JCO.2007.11.9776 17679724
11. Osako T Ito Y Takahashi S Tokudome N Iwase T Hatake K "Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer" Cancer Chemother Pharmacol 2008, 62(1):159-64. 10.1007/s00280-007-0586-5 17882419
12. Romond EH Perez EA Bryant J Suman VJ Geyer CE Jr Davidson NE Tan-Chiu E Martino S Paik S Kaufman PA Swain SM Pisansky TM Fehrenbacher L Kutteh LA Vogel VG Visscher DW Yothers G Jenkins RB Brown AM Dakhil SR Mamounas EP Lingle WL Klein PM Ingle JN Wolmark N "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer" N Engl J Med 2005, 353(16):1673-84. 10.1056/NEJMoa052122 16236738
13. Slamon D et al "Phase III randomized trial comparing doxorubicin and cyclophosphamide follone by docetaxel (ACT) with doxorubicin and cyclophosphamide follone by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breats cancer patients: BCIRG 006 study" Breast Cancer Res and Treat 2005, 94(Suppl 1):S5.
14. Joensuu H et al "Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer. The Finher trial" Breast Cancer Res and Treat 2005, 94(Suppl 1):S5.
15. Piccart-Gebhart MJ Procter M Leyland-Jones B Goldhirsch A Untch M Smith I Gianni L Baselga J Bell R Jackisch C Cameron D Dowsett M Barrios CH Steger G Huang CS Andersson M Inbar M Lichinitser M Láng I Nitz U Iwata H Thomssen C Lohrisch C Suter TM Rüschoff J Suto T Greatorex V Ward C Straehle C McFadden E Dolci MS Gelber RD Herceptin Adjuvant (HERA) Trial Study Team "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer" N Engl J Med 2005, 353(16):1659-72. 10.1056/NEJMoa052306 16236737
16. Smith I Procter M Gelber RD Guillaume S Feyereislova A Dowsett M Goldhirsch A Untch M Mariani G Baselga J Kaufmann M Cameron D Bell R Bergh J Coleman R Wardley A Harbeck N Lopez RI Mallmann P Gelmon K Wilcken N Wist E Sánchez Rovira P Piccart-Gebhart MJ HERA study team "2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial" Lancet 2007, 369(9555):29-36. 10.1016/S0140-6736(07)60028-2 17208639
17. Buzdar AU Ibrahim NK Francis D Booser DJ Thomas ES Theriault RL Pusztai L Green MC Arun BK Giordano SH Cristofanilli M Frye DK Smith TL Hunt KK Singletary SE Sahin AA Ewer MS Buchholz TA Berry D Hortobagyi GN "Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer" J Clin Oncol 2005, 23(16):3676-85. 10.1200/JCO.2005.07.032 15738535
18. Buzdar AU Valero V Ibrahim NK Francis D Broglio KR Theriault RL Pusztai L Green MC Singletary SE Hunt KK Sahin AA Esteva F Symmans WF Ewer MS Buchholz TA Hortobagyi GN "Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen" Clin Cancer Res 2007, 13(1):228-33. 10.1158/ 1078-0432.CCR-06-1345 17200359
19. Cunningham D Humblet Y Siena S Khayat D Bleiberg H Santoro A Bets D Mueser M Harstrick A Verslype C Chau I Van Cutsem E "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer" N Engl J Med 2004, 351(4):337-45. 10.1056/NEJMoa033025 15269313
20. Saltz LB Lenz HJ Kindler HL Hochster HS Wadler S Hoff PM Kemeny NE Hollywood EM Gonen M Quinones M Morse M Chen HX "Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study" J Clin Oncol 2007, 25(29):4557-61. 10.1200/JCO.2007.12.0949 17876013
21. Bonner JA Harari PM Giralt J Azarnia N Shin DM Cohen RB Jones CU Sur R Raben D Jassem J Ove R Kies MS Baselga J Youssoufian H Amellal N Rowinsky EK Ang KK "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck" N Engl J Med 2006, 354:567-78. 10.1056/NEJMoa053422 16467544
22. Burtness B Goldwasser MA Flood W Mattar B Forastiere AA Eastern Cooperative Oncology Group "Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: An Eastern Cooperative Oncology Group study" J Clin Oncol 2005, 23(34):8646-54. Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724. 10.1200/JCO.2005.02.4646 16314626
23. Vermorken JB "Cetuximab extends serviva of patients with or recurrent or metastatic SCCHN when added to first line platinum-based therapy: Results of a randomized phase III (EXTREME) study" 43th ASCO Annual Meeting, Chicago, June 1-5 2007.
24. Rosell R Robinet G Szczesna A Ramlau R Constenla M Mennecier BC Pfeifer W O'Byrne KJ Welte T Kolb R Pirker R Chemaissani A Perol M Ranson MR Ellis PA Pilz K Reck M "Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer" Ann Oncol 2008, 19(2):362-9. 10.1093/annonc/mdm474 17947225
25. Hurwitz H Fehrenbacher L Novotny W Cartwright T Hainsworth J Heim W Berlin J Baron A Griffing S Holmgren E Ferrara N Fyfe G Rogers B Ross R Kabbinavar F "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" N Engl J Med 2004, 350(23):2335-42. 10.1056/NEJMoa032691 15175435
26. Giantonio BJ Catalano PJ Meropol NJ O'Dwyer PJ Mitchell EP Alberts SR Schwartz MA Benson AB 3rd Eastern Cooperative Oncology Group Study E3200 "Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200" J Clin Oncol 2007, 25(12):1539-44. 10.1200/JCO.2006.09.6305 17442997
27. Hochster HS Hart LL Ramanathan RK Childs BH Hainsworth JD Cohn AL Wong L Fehrenbacher L Abubakr Y Saif MW Schwartzberg L Hedrick E "Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study" J Clin Oncol 2008, 26(21):3523-9. 10.1200/JCO.2007.15.4138 18640933
28. Saltz LB Clarke S Díaz-Rubio E Scheithauer W Figer A Wong R Koski S Lichinitser M Yang TS Rivera F Couture F Sirzén F Cassidy J "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study" J Clin Oncol 2008, 26(12):2013-9. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110 10.1200/JCO.2007.14.9930 18421054
29. Miller K Wang M Gralow J Dickler M Cobleigh M Perez EA Shenkier T Cella D Davidson NE "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer" N Engl J Med 2007, 357(26):2666-76. 10.1056/NEJMoa072113 18160686
30. Escudier B Pluzanska A Koralewski P Ravaud A Bracarda S Szczylik C Chevreau C Filipek M Melichar B Bajetta E Gorbunova V Bay JO Bodrogi I Jagiello-Gruszfeld A Moore N AVOREN Trial investigatore "Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial" Lancet 2007, 370(9605):2103-11. 10.1016/S0140-6736(07)61904-7 18156031
31. Herbst RS O'Neill VJ Fehrenbacher L Belani CP Bonomi PD Hart L Melnyk O Ramies D Lin M Sandler A "Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer" J Clin Oncol 2007, 25(30):4743-50. 10.1200/ JCO.2007.12.3026 17909199
32. Sandler A Gray R Perry MC Brahmer J Schiller JH Dowlati A Lilenbaum R Johnson DH "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer" N Engl J Med 2006, 355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318 10.1056/NEJMoa061884 17167137
33. Shepherd FA Rodrigues Pereira J Ciuleanu T Tan EH Hirsh V Thongprasert S Campos D Maoleekoonpiroj S Smylie M Martins R van Kooten M Dediu M Findlay B Tu D Johnston D Bezjak A Clark G Santabárbara P Seymour L National Cancer Institute of Canada Clinical Trials Group "Erlotinib in previously treated non-small-cell lung cancer" N Engl J Med 2005, 353(2):123-32. 10.1056/NEJMoa050753 16014882
34. Herbst RS Prager D Hermann R Fehrenbacher L Johnson BE Sandler A Kris MG Tran HT Klein P Li X Ramies D Johnson DH Miller VA TRIBUTE Investigator Group "TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer" J Clin Oncol 2005, 23(25):5892-9. 10.1200/JCO.2005.02.840 16043829
35. Gatzemeier U Pluzanska A Szczesna A Kaukel E Roubec J De Rosa F Milanowski J Karnicka-Mlodkowski H Pesek M Serwatowski P Ramlau R Janaskova T Vansteenkiste J Strausz J Manikhas GM Von Pawel J "Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial" J Clin Oncol 2007, 25(12):1545-5. 10.1200/JCO.2005.05.1474 17442998
36. Burris HA 3rd Hurwitz HI Dees EC Dowlati A Blackwell KL O'Neil B Marcom PK Ellis MJ Overmoyer B Jones SF Harris JL Smith DA Koch KM Stead A Mangum S Spector NL "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas" J Clin Oncol 2005, 23(23):5305-13. 10.1200/JCO.2005.16.584 15955900
37. Geyer CE Forster J Lindquist D Chan S Romieu CG Pienkowski T Jagiello-Gruszfeld A Crown J Chan A Kaufman B Skarlos D Campone M Davidson N Berger M Oliva C Rubin SD Stein S Cameron D "Lapatinib plus capecitabine for HER2-positive advanced breast cancer" N Engl J Med 2006, 355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487 10.1056/NEJMoa064320 17192538
38. Cameron D Casey M Press M Lindquist D Pienkowski T Romieu CG Chan S Jagiello-Gruszfeld A Kaufman B Crown J Chan A Campone M Viens P Davidson N Gorbounova V Raats JI Skarlos D Newstat B Roychowdhury D Paoletti P Oliva C Rubin S Stein S Geyer CE "A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses" Breast Cancer Res Treat 2008, 112(3):533-43. 10.1007/s10549-007-9885-0 18188694
39. Motzer RJ Hutson TE Tomczak P Michaelson MD Bukowski RM Rixe O Oudard S Negrier S Szczylik C Kim ST Chen I Bycott PW Baum CM Figlin RA "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma" N Engl J Med 2007, 356(2):115-24. 10.1056/NEJMoa065044 17215529
40. Demetri GD van Oosterom AT Garrett CR Blackstein ME Shah MH Verweij J McArthur G Judson IR Heinrich MC Morgan JA Desai J Fletcher CD George S Bello CL Huang X Baum CM Casali PG "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial" Lancet 2006, 368(9544):1329-38. 10.1016/S0140-6736(06)69446-4 17046465
41. Demetri GD von Mehren M Blanke CD Abbeele Van den AD Eisenberg B Roberts PJ Heinrich MC Tuveson DA Singer S Janicek M Fletcher JA Silverman SG Silberman SL Capdeville R Kiese B Peng B Dimitrijevic S Druker BJ Corless C Fletcher CD Joensuu H "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors" N Engl J Med 2002, 347(7):472-80. 10.1056/NEJMoa020461 12181401
42. Escudier B Eisen T Stadler WM Szczylik C Oudard S Siebels M Negrier S Chevreau C Solska E Desai AA Rolland F Demkow T Hutson TE Gore M Freeman S Schwartz B Shan M Simantov R Bukowski RM TARGET Study Group "Sorafenib in advanced clear-cell renal-cell carcinoma" N Engl J Med 2007, 356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203 10.1056/NEJMoa060655 17215530
43. Llovet JM Ricci S Mazzaferro V Hilgard P Gane E Blanc JF de Oliveira AC Santoro A Raoul JL Forner A Schwartz M Porta C Zeuzem S Bolondi L Greten TF Galle PR Seitz JF Borbath I Häussinger D Giannaris T Shan M Moscovici M Voliotis D Bruix J SHARP Investigators Study Group "Sorafenib in advanced hepatocellular carcinoma" N Engl J Med 2008, 359(4):378-90. 10.1056/NEJMoa0708857 18650514